Sino Biopharmaceutical (SBMFF)
(Delayed Data from OTC)
$0.37 USD
0.00 (0.00%)
Updated May 31, 2024 10:25 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SBMFF 0.37 0.00(0.00%)
Will SBMFF be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SBMFF based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for SBMFF
Sino Biopharmaceutical’s FS222 Shows Promising Results
Sino Biopharmaceutical Shareholders Approve Resolutions
Sino Biopharmaceutical Announces Board Update
Sino Biopharmaceutical Announces Executive Retirement
Sino Biopharmaceutical Adjusts Bond Conversion Price